Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.

Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, Monaghan KP, Garcia A, Rangaraju S, Giuffrida A, Plank D, Crossley G, Nugent D, Khaytin I, Lefievre Y, Peshenko I, Dixon C, Chauhan S, Orzel A, Inoue T, Hu X, Moore RV, Norton RS, Chandy KG.

Mol Pharmacol. 2009 Apr;75(4):762-73. doi: 10.1124/mol.108.052704. Epub 2009 Jan 2.

2.

Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.

Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flügel A, Pennington MW, Parker I, Chandy KG, Cahalan MD.

Immunity. 2008 Oct 17;29(4):602-14. doi: 10.1016/j.immuni.2008.07.015. Epub 2008 Oct 2.

3.

The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.

Beeton C, Smith BJ, Sabo JK, Crossley G, Nugent D, Khaytin I, Chi V, Chandy KG, Pennington MW, Norton RS.

J Biol Chem. 2008 Jan 11;283(2):988-97. Epub 2007 Nov 5.

4.

Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis.

Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H.

J Invest Dermatol. 2007 Jun;127(6):1419-29. Epub 2007 Feb 1.

5.

Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.

Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17414-9. Epub 2006 Nov 6.

6.

Potassium channels, memory T cells, and multiple sclerosis.

Beeton C, Chandy KG.

Neuroscientist. 2005 Dec;11(6):550-62. Review.

PMID:
16282596
7.

Kv1.3 potassium channel blockade as an approach to insulin resistance.

Desir GV.

Expert Opin Ther Targets. 2005 Jun;9(3):571-9. Review.

PMID:
15948674
8.

Stichodactyla helianthus peptide, a pharmacological tool for studying Kv3.2 channels.

Yan L, Herrington J, Goldberg E, Dulski PM, Bugianesi RM, Slaughter RS, Banerjee P, Brochu RM, Priest BT, Kaczorowski GJ, Rudy B, Garcia ML.

Mol Pharmacol. 2005 May;67(5):1513-21. Epub 2005 Feb 11.

9.

Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.

Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG.

Mol Pharmacol. 2005 Apr;67(4):1369-81. Epub 2005 Jan 21.

10.

K+ channels as targets for specific immunomodulation.

Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD.

Trends Pharmacol Sci. 2004 May;25(5):280-9. Review.

11.

The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.

Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG.

J Clin Invest. 2003 Jun;111(11):1703-13. Erratum in: J Clin Invest. 2003 Jul;112(2):298.

12.

A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes.

Beeton C, Wulff H, Singh S, Botsko S, Crossley G, Gutman GA, Cahalan MD, Pennington M, Chandy KG.

J Biol Chem. 2003 Mar 14;278(11):9928-37. Epub 2003 Jan 2.

13.

Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3.

Lanigan MD, Kalman K, Lefievre Y, Pennington MW, Chandy KG, Norton RS.

Biochemistry. 2002 Oct 8;41(40):11963-71.

PMID:
12356296
14.

Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.

Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, Béraud E.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13942-7.

15.

Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.

Beeton C, Barbaria J, Giraud P, Devaux J, Benoliel AM, Gola M, Sabatier JM, Bernard D, Crest M, Béraud E.

J Immunol. 2001 Jan 15;166(2):936-44.

16.

Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels.

Koo GC, Blake JT, Shah K, Staruch MJ, Dumont F, Wunderler D, Sanchez M, McManus OB, Sirotina-Meisher A, Fischer P, Boltz RC, Goetz MA, Baker R, Bao J, Kayser F, Rupprecht KM, Parsons WH, Tong XC, Ita IE, Pivnichny J, Vincent S, Cunningham P, Hora D Jr, Feeney W, Kaczorowski G, et al.

Cell Immunol. 1999 Nov 1;197(2):99-107.

PMID:
10607427
17.

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A.

Nature. 1999 Oct 14;401(6754):708-12.

PMID:
10537110
18.
19.

ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide.

Kalman K, Pennington MW, Lanigan MD, Nguyen A, Rauer H, Mahnir V, Paschetto K, Kem WR, Grissmer S, Gutman GA, Christian EP, Cahalan MD, Norton RS, Chandy KG.

J Biol Chem. 1998 Dec 4;273(49):32697-707.

20.

Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin.

Tudor JE, Pennington MW, Norton RS.

Eur J Biochem. 1998 Jan 15;251(1-2):133-41.

Supplemental Content

Support Center